Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M6,174Revenue $M214Net Margin (%)-9.8Altman Z-Score5.3
Enterprise Value $M5,942EPS $-0.3Operating Margin %-11.0Piotroski F-Score4
P/E(ttm)--Beneish M-Score-1.5Pre-tax Margin (%)-15.4Higher ROA y-yY
Price/Book22.310-y EBITDA Growth Rate %--Quick Ratio8.3Cash flow > EarningsY
Price/Sales24.55-y EBITDA Growth Rate %7.4Current Ratio8.3Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-2.8Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-7.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M120ROIC % (ttm)-2,818.4Gross Margin Increase y-yN

Gurus Latest Trades with ISIS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ISISJoel Greenblatt 2015-03-31 Reduce$58.83 - $77.08
($67.85)
$ 54.21-20%Reduce 9.75%7,892
ISISJoel Greenblatt 2014-12-31 Buy $36.46 - $65.09
($49.54)
$ 54.219%New holding8,745
ISISRon Baron 2014-06-30 Sold Out -0.01%$22.98 - $43.33
($31.44)
$ 54.2172%Sold Out0
ISISGeorge Soros 2014-06-30 Sold Out $22.98 - $43.33
($31.44)
$ 54.2172%Sold Out0
ISISRon Baron 2014-03-31 Buy 0.01%$38.56 - $59
($48.28)
$ 54.2112%New holding45,251
ISISGeorge Soros 2014-03-31 Buy $38.56 - $59
($48.28)
$ 54.2112%New holding5,539
ISISGeorge Soros 2011-06-30 Sold Out $8.54 - $9.38
($8.92)
$ 54.21508%Sold Out0
ISISGeorge Soros 2011-03-31 Buy $8.57 - $10.35
($9.21)
$ 54.21489%New holding22,300
ISISFirst Eagle Investment 2010-12-31 Sold Out -0.01%$8.05 - $10.51
($9.48)
$ 54.21472%Sold Out0
ISISFirst Eagle Investment 2010-09-30 Buy 0.01%$7.775 - $10.07
($8.76)
$ 54.21519%New holding100,000
ISISGeorge Soros 2010-09-30 Sold Out $7.775 - $10.07
($8.76)
$ 54.21519%Sold Out0
ISISGeorge Soros 2010-06-30 Buy $8.84 - $11.13
($9.93)
$ 54.21446%New holding16,100
ISISFirst Eagle Investment 2010-03-31 Sold Out -0.01%$8.66 - $11.76
($10.31)
$ 54.21426%Sold Out0
ISISFirst Eagle Investment 2009-12-31 Buy 0.01%$9.94 - $14.16
($11.94)
$ 54.21354%New holding50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ISIS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ISIS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PARSHALL B LYNNECOO & Secretary 2015-07-06Sell6,218$57.01-4.26view
CROOKE STANLEY TChairman and CEO 2015-07-06Sell6,175$57.01-4.26view
Monia Brett PSVP, Antisense Drug Discovery 2015-07-02Sell198$56.3-3.06view
PARSHALL B LYNNECOO & Secretary 2015-07-01Sell6,218$57.56-5.18view
CROOKE STANLEY TChairman and CEO 2015-07-01Sell6,175$57.56-5.18view
Monia Brett PSVP, Antisense Drug Discovery 2015-06-08Sell7,600$66.22-17.58view
MUTO FREDERICK TDirector 2015-06-01Sell10,000$66.91-18.43view
PARSHALL B LYNNECOO & Secretary 2015-04-07Sell5,565$63.07-13.46view
CROOKE STANLEY TChairman and CEO 2015-04-07Sell22,377$63.07-13.46view
PARSHALL B LYNNECOO & Secretary 2015-04-01Sell5,377$61.93-11.87view

Quarterly/Annual Reports about ISIS:

News about ISIS:

Articles On GuruFocus.com
buffet May 31 2015 
buffet May 31 2015 
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
Analysts Provide Update for Biogen, PTC Therapeutics, GW Pharma, and Isis Pharma Apr 22 2015 
Value vs. Growth: Is Jim Cramer Right about ISIS Pharmaceuticals? Dec 13 2014 
Weekly CEO Sells Highlight: Keynote Systems Inc., Isis Pharmaceuticals, Coleman Cable Inc. Jul 01 2013 
Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall sells 17,200 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley T Crooke sells 32,000 Shares Dec 29 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call Jul 28 2015
Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call Jul 28 2015
Lightning Round: $43 oil is a perfect price for it Jul 27 2015
ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related... Jul 27 2015
7:02 am ISIS Pharm reports data from its study of ISIS-TTR Rx, showing reductions in TTR protein of... Jul 27 2015
ISIS Pharmaceuticals Reports Data from ISIS-TTR Rx in patients with Transthyretin Amyloid-Related... Jul 27 2015
Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet Jul 22 2015
Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet Jul 22 2015
Isis Pharmaceuticals Begins Huntington's Disease Study - Analyst Blog Jul 22 2015
Bullish strategy in Isis, Kite Pharma Jul 22 2015
Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease Jul 21 2015
Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease Jul 21 2015
Isis Pharmaceuticals Up on Milestone Payment from Biogen - Analyst Blog Jul 15 2015
8 Companies With Accidentally Disastrous Names Jul 14 2015
Isis Pharmaceuticals Earns $2.15M For Advancing ISIS-SMN Rx in Children with Spinal Muscular Atrophy Jul 14 2015
Isis Pharmaceuticals Earns $2.15M For Advancing ISIS-SMN Rx in Children with Spinal Muscular Atrophy Jul 14 2015
Isis Pharmaceuticals' Lipid Disorder Drug Gets Orphan Status - Analyst Blog Jul 07 2015
Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII... Jul 06 2015
Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII... Jul 06 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK